Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC decreased its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 23.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 127,747 shares of the company's stock after selling 39,145 shares during the period. Nuveen Asset Management LLC owned approximately 0.24% of Janux Therapeutics worth $6,840,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Russell Investments Group Ltd. grew its stake in shares of Janux Therapeutics by 77.7% in the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after buying an additional 442 shares during the period. Meeder Asset Management Inc. purchased a new position in Janux Therapeutics in the 4th quarter valued at approximately $159,000. Tower Research Capital LLC TRC boosted its position in Janux Therapeutics by 878.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,827 shares of the company's stock valued at $205,000 after buying an additional 3,436 shares during the period. Brevan Howard Capital Management LP acquired a new stake in shares of Janux Therapeutics in the 4th quarter valued at $221,000. Finally, Chicago Capital LLC acquired a new stake in shares of Janux Therapeutics in the 4th quarter valued at $230,000. Institutional investors and hedge funds own 75.39% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on JANX shares. HC Wainwright reiterated a "buy" rating and set a $70.00 price target on shares of Janux Therapeutics in a research note on Monday, March 3rd. Wedbush reiterated an "outperform" rating and set a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Finally, Scotiabank cut their price target on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research note on Friday, February 28th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Janux Therapeutics presently has an average rating of "Buy" and an average price target of $95.25.

Insider Activity

In other news, Director Ra Capital Management, L.P. bought 110,206 shares of the stock in a transaction dated Friday, March 7th. The shares were acquired at an average price of $31.02 per share, with a total value of $3,418,590.12. Following the completion of the acquisition, the director now directly owns 10,141,287 shares in the company, valued at approximately $314,582,722.74. The trade was a 1.10% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Andrew Hollman Meyer sold 3,334 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $32.15, for a total transaction of $107,188.10. Following the sale, the insider now directly owns 82,139 shares in the company, valued at approximately $2,640,768.85. This represents a 3.90% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 10,001 shares of company stock valued at $313,964 over the last quarter. Corporate insiders own 8.10% of the company's stock.

Janux Therapeutics Stock Performance

NASDAQ JANX traded down $0.33 during trading on Friday, reaching $23.71. The company's stock had a trading volume of 1,055,845 shares, compared to its average volume of 884,498. The firm has a market cap of $1.40 billion, a price-to-earnings ratio of -20.26 and a beta of 3.24. Janux Therapeutics, Inc. has a twelve month low of $22.48 and a twelve month high of $71.71. The business's fifty day moving average price is $27.37 and its 200-day moving average price is $38.67.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. As a group, sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.